Navigation Links
Anthera Pharmaceuticals Forms Scientific Advisory Board
Date:2/5/2008

- Renowned Clinical Authorities to Advise on Development of New Drug

Candidate to Treat Autoimmune Disease -

SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has appointed the first five members of its Scientific Advisory Board for A-623, a peptide fusion protein licensed from Amgen in December 2007 for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. The scientific advisory board will include Jill Buyon, M.D., Betty Diamond, M.D., Kenneth Kalunian, M.D., David Wofsy, M.D., and Debra Zack, M.D., Ph.D.

"We are pleased to have recruited such an outstanding team of internationally recognized experts in the field of autoimmune disease," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "All have made significant contributions to the scientific understanding of lupus. The extraordinary magnitude of research and clinical expertise assembled on this board will be invaluable as we advance our clinical development programs for A-623."

-- Jill Buyon, M.D. is Professor of Medicine, New York University School

of Medicine and Vice Chairman of the Department of Rheumatology at NYU

Hospital for Joint Diseases.

-- Betty Diamond, M.D. is Head of The Center for Autoimmune and

Musculoskeletal Disease at the Feinstein Institute for Medical

Research and is on the faculty at Albert Einstein College of Medicine.

-- Kenneth Kalunian, M.D. is Professor of Medicine in the Division of

Rheumatology at the University of California, San Diego School of

Medicine.

-- David Wofsy, M.D. is Professor of Medicine and Microbiology/Immunology

at the University of California, San Francisco.

-- Debra Zack, M.D., Ph.D. is the Executive Director in Inflammation

Global Development at Amgen.

About AMG 623

AMG 623, which has completed Phase 1b studies in SLE patients, is a peptide fusion protein that binds to B-cell activating factor (BAFF). Anthera anticipates initiating Phase 2 studies in 2008. BAFF, a tumor necrosis factor family member, is critical for the survival and maturation of B cells. AMG 623 is a potent BAFF antagonist that is being developed as a treatment for B-cell dependent autoimmune diseases and is initially targeted for SLE.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory and autoimmune diseases. The Company has acquired from Eli Lilly and Company and Shionogi & Co. Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase A2 (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com.

Investor and Media Contact:

Anne Bowdidge

(650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
5. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
8. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Access Pharmaceuticals Announces $2.7 Million New Equity
10. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
11. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 ... ... Less Exposure Surgery (LES®) Technologies, announced today the next evolution in spinal ... Screw System platform). In contrast to the competition, SpineFrontier is focused on ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
(Date:1/19/2017)... -- Market Research Future has a half cooked research report on Global ... rapidly and expected to reach USD 450 Million by the end ... ... been assessed as a swiftly growing market and expected that the ... future. There has been a tremendous growth in the prevalence of ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 /PRNewswire/ ... the formation of its Medical/Clinical Advisory Board.  This ... veterans who enhance the range and depth of ... of its novel prenatal diagnostic tests.  These experts ... strategic guidance for the company,s product development and ...
Breaking Biology Technology:
(Date:1/19/2017)... PUNE, India , January 19, 2017 According to ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is ... from 2016 to 2022. In 2015, Asia-Pacific dominated the ... public and private sectors. Continue Reading ... ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/18/2017)... Jan. 18, 2017  In vitro diagnostic (IVD) companies ... and acquisitions (M&A), and Kalorama Information expects that trend ... have been shifting. Generally, uncertainty in reimbursement and healthcare ... U.S. has changed the acquisitions landscape. Instead of looking ... companies buying partners outside of their home country and ...
Breaking Biology News(10 mins):